Kamada Ltd. (NASDAQ:KMDA) is reporting third quarter financial results on Wednesday 11th November 2020, before market open.
According to analysts surveyed by Thomson Reuters, KMDA is expected to report 3Q20 income of $ 0.06 per share from revenue of $ 33.19 million.
For the full year, analysts anticipate top line of $ 134.75 million, while looking forward to income of $ 0.36 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 132.00 million ~ $ 137.00 million
Click Here For More Historical Outlooks Of Kamada Ltd.
Previous Quarter Performance
Kamada Ltd. recorded income for the second quarter of $ 0.08 per share, from the revenue of $ 33.09 million. The quarterly earnings 46.67 percent compared with the same quarter last year. Street analysts expected Kamada Ltd. to report income of $ 0.11 per share on revenue of $ 36.37 million for the second quarter. The bottom line results missed street analysts by $ 0.03 or 27.27 percent, at the same time, top line results fell short of analysts by $ 3.28 million or 9.02 percent.
Stock Performance
Shares of Kamada Ltd. traded low $ -0.14 or -2.13 percent on Tuesday, reaching $ 6.43 with volume of 319.80 thousand shares. Kamada Ltd. has traded high as $ 6.61 and has cracked $ 6.36 on the downward trend
The closing price of $ 6.43, representing a 49.32 % increase from the 52 week low of $ 4.40 and a 50.71 % decrease over the 52 week high of $ 13.33.
The company has a market capital of $ 298.18 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Kamada Ltd. will be hosting a conference call at 8:30 AM eastern time on 11th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.kamada.com
Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates through two segments, Proprietary Products and Distribution.
